secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001714899-22-000122
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali reports Q2 net loss $58.8M; collaboration revenue $52.5M on $40M Sanofi milestone
--------------------------------------------------------------------------------

- Net loss $58.8M vs $60.7M year ago; cash and securities $1.16B as of June 30, 2022.
- Collaboration revenue $52.5M, up from $22.9M, driven by $40M milestone from Sanofi (RIPK1) and $12M from Takeda (TREM2 CTA).
- R&D expenses $92.7M (+41% YoY) due to clinical progress in ETV:IDS, LRRK2, and TV platform programs.
- Phase 1 dosing started for DNL919 (ATV:TREM2) in Alzheimer’s; Phase 2b LUMA study for BIIB122 in Parkinson’s underway.
- Initiated Phase 2/3 COMPASS study for DNL310 in Hunter syndrome; data presentations planned for H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/0001714899-22-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/dnli-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001714899-22-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer